Munich – Dr. Carsten Brockmeyer, CEO of the biosimilar company Formycon AG, has again been chosen as one of the world’s top 100 most influential people in the pharmaceutical sector by the trade magazine “The Medicine Maker”. Brockmeyer was also included in the “Medicine Maker Power List” last year. Dr. Brockmeyer is joined on the list by other highly decorated people from the worlds of industry and science, including Nobel Prize winners, CEOs and a host of outstanding scientists from the pharmaceutical sector.
“I’m delighted to once again have been included in this group of outstanding people in the medicines industry. It shows that biosimilars are constantly growing in importance in the world of medicine. This further accolade also bears testimony to the services that the entire Formycon team has been contributing for years,” said Dr. Carsten Brockmeyer.
The Medicine Maker is a trade magazine published in the United Kingdom and which read all over the world. The list is compiled from readers’ nominations and assistance from experts and is based exclusively on services rendered to medicines development. The rankings are determined in three steps. First, the magazine’s readers are asked which people from the pharmaceutical industry they would include on the list. Out of these nominees, the jurors each select their 100 most influential people. These lists are then consolidated into the final document. The list can be viewed here.
Formycon is a leading, independent developer of high-quality biopharmaceutical medicines, especially biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. Based on its extensive experience in the development of biopharmaceutical drugs, the company is also working on the development of an innovative COVID-19 drug FYB207.
Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of approximately USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. Global sales of biosimilars are estimated to exceed $15 billion by 2020. By 2030, analysts estimate that this figure could rise to over $60 billion.